30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Bone Biologics Receives Approval for Trial of NB1 Growth Factor in Australia -

Bone Biologics received Human Research Ethics Committee approval for the first center of a multicenter pilot clinical trial to evaluate NB1 recombinant human protein growth factor (NELL-1/DBX®) in 30 patients in Australia. The study will examine the treatment of one-level degenerative disc disease in patients who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion. The study design has been reviewed by FDA in a Pre-submission, and is intended to support a pivotal clinical study in the U.S. (Bone Biologics Corp., 3/25/19)